Dexcom Inc (DXCM) Files Form 4 Insider Selling : Richard Doubleday Sells 3,182 Shares

industry index, md 0 Comment

Dexcom Inc (DXCM): Richard Doubleday , EVP, Chief Commercial Officer of Dexcom Inc sold 3,182 shares on Feb 23, 2017. The Insider selling transaction was reported by the company on Feb 24, 2017 to the Securities and Exchange Commission. The shares were sold at $78.42 per share for a total value of $249,529.58 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 24, 2017, Jess Roper (SVP, CFO) sold 2,333 shares at $78.76 per share price.On Feb 22, 2017, Kevin R Sayer (President & CEO) sold 10,000 shares at $81.62 per share price.Also, On Feb 14, 2017, Andrew K Balo (EVP, Clinical and Regulatory) sold 3,200 shares at $79.30 per share price.On Feb 13, 2017, John Lister (General Manager, EMEA) sold 3,000 shares at $79.74 per share price.

Shares of DexCom (DXCM) ended Wednesday, Feb 22, 2017 session in red amid volatile trading. The shares closed down -1.31 points or -1.64% at $78.59 with 8,53,838 shares getting traded. Post opening the session at $79.88, the shares hit an intraday low of $78.02 and an intraday high of $79.89 and the price vacillated in this range throughout the day. The company has a market cap of $6,643 M and the number of outstanding shares has been calculated to be 8,45,24,171 shares. The 52-week high of DexCom is $96.38 and the 52-week low is $56.52.

DexCom Money Flow Index Chart

Company has been under the radar of several Street Analysts.DexCom is Downgraded by Morgan Stanley to Equal-Weight and the brokerage firm has set the Price Target at $66. Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Jan 3, 2017.DexCom is Upgraded by Oppenheimer to Outperform. Earlier the firm had a rating of Perform on the company shares. The Rating was issued on Dec 19, 2016.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpotÂ’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Author

Fred Moore

For any feedback and suggestions contact author at Fred.Moore@themarketdigest.org

Leave a comment

Back to Top